Mint Tower Capital Management B.V. Acquires Shares of 53,052 Avanos Medical, Inc. $AVNS

Mint Tower Capital Management B.V. bought a new stake in Avanos Medical, Inc. (NYSE:AVNS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 53,052 shares of the company’s stock, valued at approximately $1,320,000. Mint Tower Capital Management B.V. owned about 0.11% of Avanos Medical as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in AVNS. Federated Hermes Inc. increased its position in Avanos Medical by 2.8% in the 4th quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock valued at $289,000 after acquiring an additional 691 shares during the period. PNC Financial Services Group Inc. lifted its position in Avanos Medical by 15.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock worth $89,000 after acquiring an additional 846 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after purchasing an additional 1,423 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of Avanos Medical by 2.1% in the 4th quarter. Swiss National Bank now owns 91,500 shares of the company’s stock valued at $1,028,000 after purchasing an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Wall Street Analysts Forecast Growth

AVNS has been the subject of several analyst reports. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

NYSE AVNS opened at $24.99 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. Avanos Medical, Inc. has a 52-week low of $9.30 and a 52-week high of $25.49. The firm has a 50-day moving average price of $24.96 and a 200 day moving average price of $21.40. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.